PDF herunterladen
Semin Neurol 2016; 36(01): 073-083
DOI: 10.1055/s-0036-1571953
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Botulinum Toxin Treatment of Neuropathic Pain

Shivam Om Mittal
1   Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, Ohio
,
Delaram Safarpour
2   Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania
,
Bahman Jabbari
3   Department of Neurology, Yale University School of Medicine, New Haven, Connecticut
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
11. Februar 2016 (online)

    Lizenzen und Reprints

Abstract

Neuropathic pain (NP), a common form of human pain, often poorly responds to analgesic medications. In this review the authors discuss the pathophysiology and conventional treatment of neuropathic pain and provide evidenced-based statements on the efficacy of botulinum neurotoxins (BoNTs) in this form of pain. The level of efficacy for BoNT treatment in each category of NP is defined according to the published guidelines of the American Academy of Neurology. The data indicate that BoNT treatment (most of the literature is with onabotulinumtoxinA) is effective (level A evidence) in postherpetic neuralgia and trigeminal neuralgia. It is probably effective (level B) in posttraumatic neuralgia and painful diabetic neuropathy. The data on complex regional pain syndrome, carpal tunnel syndrome, occipital neuralgia, and phantom limb pain are preliminary and await conduction of randomized, blinded clinical trials. Much remains to be learned about the most-effective dosage and technique of injection, optimum dilutions, and differences among BoNTs in the treatment of neuropathic pain.

Keywords

botulinum toxin - neuropathic pain - postherpetic neuralgia - posttraumatic neuralgia - diabetic neuropathy - trigeminal neuralgia - complex regional pain syndrome - phantom pain - carpal tunnel syndrome - occipital neuralgia
 

  • References

  • 1 Treede R-D. Peripheral and Central Mechanisms of Neuropathic Pain. Mechanisms, Diagnosis and Treatment. New York: Oxford University Press; 2012: 14-24
    Google Scholar
  • 2 Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord 2011; 17 (Suppl. 01) S28-S33
    CrossrefPubMedGoogle Scholar
  • 3 Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008; 101 (3) 366-370
    CrossrefPubMedGoogle Scholar
  • 4 Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 2007; 120 (Pt 16): 2864-2874
    CrossrefPubMedGoogle Scholar
  • 5 Oh H-M, Chung ME. Botulinum toxin for neuropathic pain: a review of the literature. Toxins (Basel) 2015; 7 (8) 3127-3154
    CrossrefPubMedGoogle Scholar
  • 6 Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107 (1–2) 125-133
    CrossrefPubMedGoogle Scholar
  • 7 Kharatmal SB, Singh JN, Sharma SS. Voltage-gated sodium channels as therapeutic targets for treatment of painful diabetic neuropathy. Mini Rev Med Chem 2015; 15 (14) 1134-1147
    CrossrefPubMedGoogle Scholar
  • 8 Shin MC, Wakita M, Xie DJ , et al. Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J Pharmacol Sci 2012; 118 (1) 33-42
    CrossrefPubMedGoogle Scholar
  • 9 Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993; 113 (3) 400-404
    CrossrefPubMedGoogle Scholar
  • 10 Rand MJ, Whaler BC. Impairment of sympathetic transmission by botulinum toxin. Nature 1965; 206 (984) 588-591
    CrossrefPubMedGoogle Scholar
  • 11 French J, Gronseth G. Lost in a jungle of evidence: we need a compass. Neurology 2008; 71 (20) 1634-1638
    CrossrefPubMedGoogle Scholar
  • 12 Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain 2001; 92 (1–2) 139-145
    CrossrefPubMedGoogle Scholar
  • 13 Haanpää M, Dastidar P, Weinberg A , et al. CSF and MRI findings in patients with acute herpes zoster. Neurology 1998; 51 (5) 1405-1411
    CrossrefPubMedGoogle Scholar
  • 14 Oxman MN, Levin MJ, Johnson GR , et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352 (22) 2271-2284
    CrossrefPubMedGoogle Scholar
  • 15 Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22 (2) 341-347
    CrossrefPubMedGoogle Scholar
  • 16 Whitley RJ, Weiss H, Gnann Jr JW , et al; The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. Ann Intern Med 1996; 125 (5) 376-383
    CrossrefPubMedGoogle Scholar
  • 17 Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82 (11) 1341-1349
    CrossrefPubMedGoogle Scholar
  • 18 Thyregod HG, Rowbotham MC, Peters M, Possehn J, Berro M, Petersen KL. Natural history of pain following herpes zoster. Pain 2007; 128 (1–2) 148-156
    CrossrefPubMedGoogle Scholar
  • 19 Baron R, Haendler G, Schulte H. Afferent large fiber polyneuropathy predicts the development of postherpetic neuralgia. Pain 1997; 73 (2) 231-238
    CrossrefPubMedGoogle Scholar
  • 20 Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005; 6 (6) 356-363
    CrossrefPubMedGoogle Scholar
  • 21 Cohen JI. Clinical practice: herpes zoster. N Engl J Med 2013; 369 (3) 255-263
    CrossrefPubMedGoogle Scholar
  • 22 Jeon YH. Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. Korean J Pain 2015; 28 (3) 177-184
    CrossrefPubMedGoogle Scholar
  • 23 Beiteke U, Bigge S, Reichenberger C, Gralow I. Pain and pain management in dermatology. J Dtsch Dermatol Ges 2015; 13 (10) 967-987
    PubMedGoogle Scholar
  • 24 Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med 2014; 371 (16) 1526-1533
    CrossrefPubMedGoogle Scholar
  • 25 Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain 2013; 29 (10) 857-864
    CrossrefPubMedGoogle Scholar
  • 26 Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med 2010; 11 (12) 1827-1833
    CrossrefPubMedGoogle Scholar
  • 27 Liu H-T, Tsai S-K, Kao M-C, Hu JS. Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med 2006; 7 (1) 89-91
    CrossrefPubMedGoogle Scholar
  • 28 Sotiriou E, Apalla Z, Panagiotidou D, Ioannidis D. Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports. Acta Derm Venereol 2009; 89 (2) 214-215
    PubMedGoogle Scholar
  • 29 Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008; 64 (3) 274-283
    CrossrefPubMedGoogle Scholar
  • 30 Katz J, Seltzer Z. Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Rev Neurother 2009; 9 (5) 723-744
    CrossrefPubMedGoogle Scholar
  • 31 McLachlan EM, Jänig W, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993; 363 (6429) 543-546
    CrossrefPubMedGoogle Scholar
  • 32 Garrison CJ, Dougherty PM, Kajander KC, Carlton SM. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res 1991; 565 (1) 1-7
    CrossrefPubMedGoogle Scholar
  • 33 Todd AJ, Sullivan AC. Light microscope study of the coexistence of GABA-like and glycine-like immunoreactivities in the spinal cord of the rat. J Comp Neurol 1990; 296 (3) 496-505
    CrossrefPubMedGoogle Scholar
  • 34 Yaksh TL, Chaplan SR. Physiology and pharmacology of neuropathic pain. Anesthesiol Clin North America 1997; 15 (2) 335-352
    CrossrefPubMedGoogle Scholar
  • 35 Yoshimasu F, Kurland LT, Elveback LR. Tic douloureux in Rochester, Minnesota, 1945-1969. Neurology 1972; 22 (9) 952-956
    CrossrefPubMedGoogle Scholar
  • 36 Katusic S, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol 1990; 27 (1) 89-95
    CrossrefPubMedGoogle Scholar
  • 37 Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol 1984; 15 (3) 240-244
    CrossrefPubMedGoogle Scholar
  • 38 Baschnagel AM, Cartier JL, Dreyer J , et al. Trigeminal neuralgia pain relief after gamma knife stereotactic radiosurgery. Clin Neurol Neurosurg 2014; 117: 107-111
    CrossrefPubMedGoogle Scholar
  • 39 Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004; 44 (1) 35-42 , discussion 42–43
    CrossrefPubMedGoogle Scholar
  • 40 Chichorro JG, Fiuza CR, Bressan E, Claudino RF, Leite DF, Rae GA. Endothelins as pronociceptive mediators of the rat trigeminal system: role of ETA and ETB receptors. Brain Res 2010; 1345: 73-83
    CrossrefPubMedGoogle Scholar
  • 41 Kitamura Y, Matsuka Y, Spigelman I , et al. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience 2009; 159 (4) 1422-1429
    CrossrefPubMedGoogle Scholar
  • 42 Meng J, Ovsepian SV, Wang J , et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 2009; 29 (15) 4981-4992
    CrossrefPubMedGoogle Scholar
  • 43 Shimizu T, Shibata M, Toriumi H , et al. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis 2012; 48 (3) 367-378
    CrossrefPubMedGoogle Scholar
  • 44 Matak I, Bach-Rojecky L, Filipović B, Lacković Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 2011; 186: 201-207
    CrossrefPubMedGoogle Scholar
  • 45 Wu CJ, Lian YJ, Zheng YK , et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 2012; 32 (6) 443-450
    CrossrefPubMedGoogle Scholar
  • 46 Zhang H, Lian Y, Ma Y , et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain 2014; 15 (1) 65
    CrossrefPubMedGoogle Scholar
  • 47 Zúñiga C, Piedimonte F, Díaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol 2013; 36 (5) 146-150
    CrossrefPubMedGoogle Scholar
  • 48 Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia?. J Headache Pain 2013; 14: 92
    CrossrefPubMedGoogle Scholar
  • 49 Li S, Lian YJ, Chen Y , et al. Therapeutic effect of Botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up. J Headache Pain 2014; 15: 43
    CrossrefPubMedGoogle Scholar
  • 50 Xia JH, He CH, Zhang HF , et al. Botulinum toxin A in the treatment of trigeminal neuralgia. Int J Neurosci 2015; 19: 1-6
    PubMedGoogle Scholar
  • 51 Casale R, Atzeni F, Sarzi-Puttini P. From Mitchell's causalgia to complex regional pain syndromes: 150 years of definitions and theories. Clin Exp Rheumatol 2015; 33 (1) (Suppl. 88) S7-S13
    PubMedGoogle Scholar
  • 52 Harden RN, Oaklander AL, Burton AW , et al. Complex regional pain syndrome: practical diagnostic and treatment guidelines, 4th edition. Pain Med 2013; 14 (2) 180-229
    CrossrefPubMedGoogle Scholar
  • 53 Coderre TJ, Xanthos DN, Francis L, Bennett GJ. Chronic post-ischemia pain (CPIP): a novel animal model of complex regional pain syndrome-type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the rat. Pain 2004; 112 (1–2) 94-105
    CrossrefPubMedGoogle Scholar
  • 54 Weber M, Birklein F, Neundörfer B, Schmelz M. Facilitated neurogenic inflammation in complex regional pain syndrome. Pain 2001; 91 (3) 251-257
    CrossrefPubMedGoogle Scholar
  • 55 Del Valle L, Schwartzman RJ, Alexander G. Spinal cord histopathological alterations in a patient with longstanding complex regional pain syndrome. Brain Behav Immun 2009; 23 (1) 85-91
    CrossrefPubMedGoogle Scholar
  • 56 Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain 2009; 147 (1–3) 107-115
    CrossrefPubMedGoogle Scholar
  • 57 Goebel A, Baranowski A, Maurer K, Ghiai A, McCabe C, Ambler G. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. Ann Intern Med 2010; 152 (3) 152-158
    CrossrefPubMedGoogle Scholar
  • 58 Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2002; 18 (6, Suppl) S177-S181
    CrossrefPubMedGoogle Scholar
  • 59 Birthi P, Sloan P, Salles S. Subcutaneous botulinum toxin A for the treatment of refractory complex regional pain syndrome. PM R 2012; 4 (6) 446-449
    CrossrefPubMedGoogle Scholar
  • 60 Safarpour D, Salardini A, Richardson D, Jabbari B. Botulinum toxin A for treatment of allodynia of complex regional pain syndrome: a pilot study. Pain Med 2010; 11 (9) 1411-1414
    CrossrefPubMedGoogle Scholar
  • 61 Safarpour D, Jabbari B. Botulinum toxin A (Botox) for treatment of proximal myofascial pain in complex regional pain syndrome: two cases. Pain Med 2010; 11 (9) 1415-1418
    CrossrefPubMedGoogle Scholar
  • 62 Kharkar S, Ambady P, Yedatore V, Schwartzman RJ. Intramuscular botulinum toxin A (BtxA) in complex regional pain syndrome. Pain Physician 2011; 14 (3) 311-316
    PubMedGoogle Scholar
  • 63 Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007; 8 (Suppl. 02) S50-S62
    CrossrefPubMedGoogle Scholar
  • 64 Boulton AJM. Diabetic neuropathy: classification, measurement and treatment. Curr Opin Endocrinol Diabetes Obes 2007; 14 (2) 141-145
    CrossrefPubMedGoogle Scholar
  • 65 Romanovsky D, Cruz NF, Dienel GA, Dobretsov M. Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats. Neurobiol Dis 2006; 24 (2) 384-394
    CrossrefPubMedGoogle Scholar
  • 66 Orestes P, Osuru HP, McIntire WE , et al. Reversal of neuropathic pain in diabetes by targeting glycosylation of Ca(V)3.2 T-type calcium channels. Diabetes 2013; 62 (11) 3828-3838
    CrossrefPubMedGoogle Scholar
  • 67 Bril V, England J, Franklin GM , et al; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76 (20) 1758-1765 . [Dosage error corrected in Neurology 2011;77(6):603]
    CrossrefPubMedGoogle Scholar
  • 68 Javed S, Alam U, Malik RA. Burning through the pain: treatments for diabetic neuropathy. Diabetes Obes Metab 2015; 17 (12) 1115-1125
    CrossrefPubMedGoogle Scholar
  • 69 Hong L, Zhang J, Shen J. Clinical efficacy of different doses of lipo-prostaglandin E1 in the treatment of painful diabetic peripheral neuropathy. J Diabetes Complications 2015; 29 (8) 1283-1286
    CrossrefPubMedGoogle Scholar
  • 70 Yuan RY, Sheu JJ, Yu JM , et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009; 72 (17) 1473-1478
    CrossrefPubMedGoogle Scholar
  • 71 Chen W-T, Yuan R-Y, Chiang S-C , et al. OnabotulinumtoxinA improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain 2013; 29 (4) 305-310
    CrossrefPubMedGoogle Scholar
  • 72 Ziegler-Graham K, MacKenzie EJ, Ephraim PL, Travison TG, Brookmeyer R. Estimating the prevalence of limb loss in the United States: 2005 to 2050. Arch Phys Med Rehabil 2008; 89 (3) 422-429
    CrossrefPubMedGoogle Scholar
  • 73 Carlen PL, Wall PD, Nadvorna H, Steinbach T. Phantom limbs and related phenomena in recent traumatic amputations. Neurology 1978; 28 (3) 211-217
    CrossrefPubMedGoogle Scholar
  • 74 Jensen TS, Krebs B, Nielsen J, Rasmussen P. Phantom limb, phantom pain and stump pain in amputees during the first 6 months following limb amputation. Pain 1983; 17 (3) 243-256
    CrossrefPubMedGoogle Scholar
  • 75 Hsu E, Cohen SP. Postamputation pain: epidemiology, mechanisms, and treatment. J Pain Res 2013; 6: 121-136
    PubMedGoogle Scholar
  • 76 Alviar MJM, Hale T, Dungca M. Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst Rev 2011; 12 (12) CD006380
    PubMedGoogle Scholar
  • 77 Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans: results of a survey. Pain 1984; 18 (1) 83-95
    CrossrefPubMedGoogle Scholar
  • 78 Kern U, Martin C, Scheicher S, Müller H. Effects of botulinum toxin type B on stump pain and involuntary movements of the stump. Am J Phys Med Rehabil 2004; 83 (5) 396-399
    CrossrefPubMedGoogle Scholar
  • 79 Jin L, Kollewe K, Krampfl K, Dengler R, Mohammadi B. Treatment of phantom limb pain with botulinum toxin type A. Pain Med 2009; 10 (2) 300-303
    CrossrefPubMedGoogle Scholar
  • 80 Wu H, Sultana R, Taylor KB, Szabo A. A prospective randomized double-blinded pilot study to examine the effect of botulinum toxin type A injection versus Lidocaine/Depomedrol injection on residual and phantom limb pain: initial report. Clin J Pain 2012; 28 (2) 108-112
    CrossrefPubMedGoogle Scholar
  • 81 Brown EA, Schütz SG, Simpson DM. Botulinum toxin for neuropathic pain and spasticity: an overview. Pain Manag 2014; 4 (2) 129-151
    CrossrefPubMedGoogle Scholar